4.7 Article

The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer

Journal

BRITISH JOURNAL OF CANCER
Volume 127, Issue 1, Pages 137-144

Publisher

SPRINGERNATURE
DOI: 10.1038/s41416-022-01788-5

Keywords

-

Categories

Funding

  1. Wellcome Trust [110104/Z/15/Z]
  2. Wellcome Trust [110104/Z/15/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

This article presents the experience of the East of England Genomic Medicine Centre in conducting centralized WGS for children with cancer during the 100 K project, reporting its feasibility and clinical utility. The study found that WGS provided additional clinical value in the diagnosis of pediatric cancer, but also highlighted the need for local expertise in scrutinizing and clinically interpreting variant calls derived from centralized analysis.
Background Whole-genome sequencing (WGS) of cancers is becoming an accepted component of oncological care, and NHS England is currently rolling out WGS for all children with cancer. This approach was piloted during the 100,000 genomes (100 K) project. Here we share the experience of the East of England Genomic Medicine Centre (East-GMC), reporting the feasibility and clinical utility of centralised WGS for individual children locally. Methods Non-consecutive children with solid tumours were recruited into the pilot 100 K project at our Genomic Medicine Centre. Variant catalogues were returned for local scrutiny and appraisal at dedicated genomic tumour advisory boards with an emphasis on a detailed exploration of potential clinical value. Results Thirty-six children, representing one-sixth of the national 100 K cohort, were recruited through our Genomic Medicine Centre. The diagnoses encompassed 23 different solid tumour types and WGS provided clinical utility, beyond standard-of-care assays, by refining (2/36) or changing (4/36) diagnoses, providing prognostic information (8/36), defining pathogenic germline mutations (1/36) or revealing novel therapeutic opportunities (8/36). Conclusion Our findings demonstrate the feasibility and clinical value of centralised WGS for children with cancer. WGS offered additional clinical value, especially in diagnostic terms. However, our experience highlights the need for local expertise in scrutinising and clinically interpreting centrally derived variant calls for individual children.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available